A First-in-Human, Phase 1a/1b Trial to Assess the Safety, Tolerability and Preliminary Efficacy ofLY4175408, an Antibody Drug Conjugate Targeting Protein Tyrosine Kinase 7-Expressing TumorCells, in Participants with Selected Advanced Solid Tumors

The purpose of this study is to learn about the effects of the study drug, LY4175408, to find the best dose for treating advanced/metastatic (meaning the cancer has spread beyond where it started to other parts of the body) cancers and to see how safe LY4175408 is for patients with advanced/metastatic cancers. LY4175408 is an “investigational” drug in this study because it has not been approved by The United States Food and Drug Administration (FDA), the health authority that gives approval for new medicines in the United States.

Are you Eligible? (Inclusion Criteria)

• Is ≥18 years of age inclusive or the legal age of consent in the jurisdiction in which the study is taking place, at the time of signing the informed consent. 2. Has received all standard therapies for which the individual was deemed to be an appropriate candidate by the treating investigator; OR the individual is refusing the remaining most appropriate standard of care treatment; OR there is no standard therapy available for the disease. 3. Is able to comply with outpatient treatment, laboratory monitoring, and required clinic visits for the duration of trial participation.